Journal of Clinical Oncology
Articles in this Issue
Association of <i>ALOX12B</i> gene alterations with TMB and immune checkpoint inhibitor (ICI) outcomes.
e14546 Background: ALOX12B encodes 12R-lipoxygenase (12R-LOX), an arachidonic-acidlipoxygenase that generates fatty-acid h...
Diagnostic performance of serum PIVKA-II alone and in combination with AFP for hepatocellular carcinoma: A comparative retrospective study.
e15064 Background: Protein-Induced by Vitamin K Absence-II (PIVKA-II), being mechanistically linked to Hepatocellular carc...
Phase I trial of the anti-CAPRIN1 antibody TRK-950 alone or with nivolumab in Japanese patients with advanced solid tumors.
2525 Background: CAPRIN-1 is expressed on the tumor-cell membrane across many solid cancers but not on normal cells. TRK-9...
Real-world efficacy of cetuximab after immune checkpoint inhibitor and platin failure in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A 10-year retrospective study in 124 patients.
e18025 Background: In R/M HNSCC, cetuximab monotherapy historically yields an objective response rate (ORR) of 13%. Emergi...
Integrating overall survival and quality of life to rank first-line therapies for advanced urothelial carcinoma.
e16588 Background: While survival advantages of first-line therapies for locally advanced or metastatic urothelial carcino...
Temporal trends and disparities in sudden cardiac death among pancreatic cancer patients in the United States.
e16438 Background: In patients with pancreatic cancer, sudden cardiac death (SCD) is an overlooked terminal event. There i...
Use of patient-centered versus disease-centered language in public-facing media from National Cancer Institute–designated Comprehensive Cancer Centers.
e23123 Background: Receiving a cancer diagnosis often requires emotional and informational support. The way health informa...
TSY-310, a novel bispecific EGFR×ROR1 ADC: Assessment of antitumor activity in heterogeneous breast tumors through enhanced internalization and bystander cytotoxicity.
3086 Background: Epidermal growth factor receptor (EGFR) is a clinically validated target and is highly expressed in vario...
What do patients undergoing androgen deprivation therapy think about exercise interventions and the use of wearable activity monitors?
e17091 Background: Exercise is critical for the prevention of functional decline and maintaining overall health, especiall...
<i>Bacteroides sp. DH3716P</i> and mediation of immunotherapy response in oligometastatic nasopharyngeal carcinoma via the gut–nasopharyngeal axis.
6031 Background: Predictors of benefit from gemcitabine/cisplatin (GP) plus PD-1 blockade in oligometastatic nasopharyngea...
Early operative management versus nonoperative care for cancer-associated small bowel obstruction in patients with recent peritoneal metastasis: A real-world propensity-matched analysis.
e15574 Background: Cancer-associated small bowel obstruction (SBO) is a morbid complication of advanced malignancy; malign...
Drivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer.
e20541 Background: The non-random distribution of metastases (mets) to distant organ sites, known as organotropism, has be...
Transforming renal cell carcinoma outcomes: The paradigm shift influenced by immune checkpoint inhibitors.
e16559 Background: Renal Cell Carcinoma (RCC) is a malignancy that arises from the renal tubular epithelial cells. It has...
Real-time breath volatile organic compound analysis for detection of newly diagnosed, treatment naïve non-small cell lung cancer: A pilot study.
e22525 Background: Non-small cell lung cancer (NSCLC) is highly lethal as most cases are late stage at diagnosis. Screenin...
Adjuvant chemotherapy (CT) benefit in invasive lobular carcinoma (ILC) by Oncotype DX Recurrence Score and menopausal status.
540 Background: The benefit of adjuvant CT in early-stage hormone receptor–positive (HR+) and HER2-negative (HER2–) ILC re...
BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.
TPS3160 Background: BNT326/YL202 is an investigational ADC composed of an anti-HER3 IgG1 monoclonal antibody conjugated to...
Albumin–bilirubin index as a determinant of short- and long-term outcomes after locoregional therapy for hepatocellular carcinoma: A real-world propensity-matched analysis.
e16304 Background: Hepatic reserve is a critical determinant of outcomes in hepatocellular carcinoma (HCC), yet traditiona...
Application of PET RANO 1.0 criteria and associations with outcome in <i>IDH-</i> mutant gliomas: A retrospective cohort study.
2075 Background: Amino acid PET is increasingly used to guide clinical decisions in glioma. For standardized response asse...
B cell responses in recurrent respiratory papillomatosis patients treated with DNA immunotherapy INO-3107.
2549 Background: Recurrent respiratory papillomatosis (RRP) is a chronic, debilitating disease of the airway primarily cau...
Impact of a patient-facing app to address surgical oncology patients’ social determinants of health: Preliminary results of a phase II clinical trial.
1570 Background: Unmet Social Determinants of Health (SDH) needs, including housing, transportation, food insecurity, util...
Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.
1067 Background: Substudy A of the open-label, phase 1b/2 TACTIVE-U umbrella study is evaluating vepdegestrant, an oral PR...
Phase 2 basket trial of precision TIL therapy for immunotherapy-resistant advanced cancers.
2505 Background: Adoptive cell therapy (ACT) using unselected autologous tumor-infiltrating lymphocytes (TIL) has demonstr...
Trends and disparities in mortality from malignant neoplasms of male genital organs in the United States, 1999–2023.
11134 Background: Genital malignant neoplasms remain an important cause of mortality among males living in the United Stat...
GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies.
TPS649 Background: While advancements in early-stage breast cancer (ESBC) treatment have improved survival, disease recurr...
Integrated data platform: Backbone of cancer research office.
e13653 Background: The management of research portfolio and workflow is crucial for every research entity in a cancer cent...